Mary Moree, MD
Family Medicine · Laurinburg, NCNPI 1235457714
Payments from drug & device makers
Across 397 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$676
- AbbVie$653
- Boehringer Ingelheim$548
- Lilly USA, LLC$510
- GSK$338
- plus $2K from 34 others
What the payments were for
- Food & beverage$6,196100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 85 | $1,167 |
| AstraZeneca | 41 | $676 |
| AbbVie | 36 | $653 |
| Boehringer Ingelheim | 34 | $548 |
| Lilly USA, LLC | 34 | $510 |
| GSK | 24 | $338 |
| Pfizer | 23 | $320 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $245 |
| Sanofi-aventis U.S. LLC | 10 | $175 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $154 |
| Novartis | 10 | $151 |
| Merck | 10 | $147 |
| Mylan Specialty L.p. | 8 | $143 |
| Exact Sciences | 8 | $135 |
| Amarin Pharma, Inc. | 6 | $99 |
| Phathom Pharmaceuticals, Inc. | 4 | $87 |
| Amgen | 6 | $83 |
| Shield Therapeutics Inc | 3 | $50 |
| Davol Inc. | 1 | $49 |
| Idorsia Pharmaceuticals US Inc | 2 | $43 |
| Abbott | 2 | $42 |
| Johnson & Johnson | 3 | $39 |
| Corcept Therapeutics | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 2 | $29 |
| Eisai Inc. | 2 | $27 |
| Daiichi Sankyo Inc. | 2 | $26 |
| Viatris Specialty LLC | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Bayer | 1 | $18 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
| Organon | 1 | $10 |
How this compares
$6,206 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 78 | $87,808 |
| OzempicSemaglutide | 58 | $70,094 |
| EliquisApixaban | 76 | $67,496 |
| JardianceEmpagliflozin | 58 | $44,763 |
| JanuviaSitagliptin Phosphate | 51 | $32,815 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $28,235 |
| LinzessLinaclotide | 46 | $25,639 |
| MyrbetriqMirabegron | 20 | $25,458 |
| MounjaroTirzepatide | 22 | $23,215 |
| XareltoRivaroxaban | 17 | $17,719 |
| Trokendi XrTopiramate | 13 | $17,025 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $9,971 |
| Bydureon BciseExenatide Microspheres | 12 | $9,825 |
| FarxigaDapagliflozin Propanediol | 11 | $9,743 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $510 | $111,022100 claims |
| Novo NordiskOzempic, Novolog Mix 70-30 | $1,167 | $71,29975 claims |
| PfizerEliquis | $320 | $67,49676 claims |
| Boehringer IngelheimJardiance | $548 | $44,76358 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $338 | $33,36335 claims |
| MerckJanuvia | $147 | $32,81551 claims |
| AbbVieLinzess, Viibryd, Synthroid | $653 | $31,11870 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $25,45820 claims |
| Johnson & JohnsonXarelto | $39 | $17,71917 claims |
| AstraZenecaFarxiga, Symbicort | $676 | $14,90627 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $12 | $5,03211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Laurinburg
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.